New therapeutic target for pancreatic cancer

New experiments have shown how the "Seven-In-Absentia-Homolog" protein targets a key pathway for pancreatic cancer. And the research at the Mayo Clinic College of Medicine in Minnesota points to a new approach to treating the lethal disease.

Scientists already knew that a mutation in the K-RAS gene underlies the abnormal, excessive cell growth of pancreatic cancer. Because the mutated form of this growth-promoting gene is hyperactivated, a major signaling pathway that drives cell growth is in over-drive in most patients with this cancer.

The "Seven-In-Absentia-Homolog" protein seems to work as a check and balance mechanism in the K-RAS pathway by chewing up and turning off the excessive growth-promoting proteins produced by the hyperactive, mutated form of the gene, says Amy Tang whose Mayo lab conducted the research. "By attacking the SIAH-based protein-degrading machinery, we block tumor formation in one of the most aggressive human cancers cells known."

- check out the release

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.